University of Oxford

Bexorg completed a $23 million Series A financing led by Engine Ventures, bringing total funding to $42.5 million to advance its integrated AI and whole-human brain platform for CNS drug development.

DaltonTx, a UK-based technology company, has completed a £4 million seed financing round to develop adaptive AI-enabled discovery platforms that reshape R&D economics and timelines.

Dexpramipexole met its primary endpoint in the EXHALE-4 Phase III study, demonstrating statistically significant improvement in lung function compared to placebo in patients with eosinophilic asthma.

Genentech has entered an exclusive collaboration with OMass Therapeutics to develop oral small molecules targeting a first-in-class inflammatory bowel disease target, with $20 million upfront and over $400 million in potential milestone payments.

OrganOx, the Oxford-based medtech company behind pioneering liver perfusion technology, has been acquired by Terumo Corporation for approximately $1.5 billion.

Circle Pharma's CID-078, a first-in-class oral cyclin A/B RxL inhibitor, demonstrated robust anti-tumor activity in preclinical models, including chemotherapy-resistant small cell lung cancer xenografts.

Upperton Pharma Solutions has secured funding from the VaxHub Sustainable Platform Funding Call to develop an oral formulation for adenovirus-vectored vaccines in collaboration with the University of Oxford.

MIT researchers used generative AI to design two novel antibiotics capable of killing drug-resistant gonorrhea and MRSA in laboratory and animal tests.

Ultromics raised $55 million in Series C funding to expand its FDA-cleared EchoGo platform for detecting heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis across US hospitals.

The BOHEMIA trial, the largest study on ivermectin for malaria to date, demonstrated a 26% reduction in new malaria infections when administered alongside standard bed nets in Kenya.